| 4 | Deep Track Capital, LP | 9.3M | $49.4M | 0.0% | 6.691% | 0.72% |
| 5 | Vivo Capital, LLC | 6.7M | $35.4M | +0.4% | 4.793% | 3.23% |
| 6 | VANGUARD CAPITAL MANAGEMENT LLC | 5.8M | $30.8M | +12.6% | 4.166% | 0.00% |
| 7 | Frazier Life Sciences Management, L.P. | 4.9M | $26.1M | 0.0% | 3.527% | 0.57% |
| 8 | Rock Springs Capital Management LP | 4.3M | $22.9M | -3.2% | 3.101% | 1.12% |
| 9 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 4.1M | $21.5M | +5.2% | 2.915% | 0.03% |
| 10 | Decheng Capital LLC | 4.0M | $21.4M | 0.0% | 2.894% | 2.92% |
| 11 | STATE STREET CORP | 3.3M | $17.2M | +62.1% | 2.331% | 0.00% |
| 12 | GEODE CAPITAL MANAGEMENT, LLC | 3.2M | $16.9M | +31.6% | 2.284% | 0.00% |
| 13 | CITADEL ADVISORS LLC | 2.4M | $12.6M | -15.3% | 1.709% | 0.00% |
| 14 | BRAIDWELL LP | 2.1M | $11.3M | +26.1% | 1.534% | 0.42% |
| 15 | BALYASNY ASSET MANAGEMENT L.P. | 2.0M | $10.7M | -39.8% | 1.449% | 0.01% |
| 16 | SILVERARC CAPITAL MANAGEMENT, LLC | 1.9M | $10.3M | — | 1.394% | 1.07% |
| 17 | Kalehua Capital Management LLC | 1.8M | $9.7M | 0.0% | 1.312% | 3.09% |
| 18 | Jones Hill Capital LP | 1.8M | $9.3M | — | 1.260% | 1.98% |
| 19 | Palo Alto Investors LP | 1.6M | $8.5M | 0.0% | 1.155% | 0.39% |
| 20 | Woodline Partners LP | 1.6M | $8.5M | +8.4% | 1.153% | 0.03% |
| 21 | VANGUARD PORTFOLIO MANAGEMENT LLC | 1.5M | $7.8M | -11.5% | 1.050% | 0.00% |
| 22 | PANAGORA ASSET MANAGEMENT INC | 1.4M | $7.2M | +170.0% | 0.971% | 0.02% |
| 23 | Connor, Clark & Lunn Investment Management Ltd. | 1.2M | $6.4M | -14.7% | 0.866% | 0.01% |
| 24 | MPM BioImpact LLC | 1.0M | $5.5M | +166.0% | 0.746% | 0.34% |
| 25 | DEUTSCHE BANK AG\ | 1.0M | $5.5M | +4.3% | 0.745% | 0.00% |
denotes a marquee investor (Buffett, Burry, ARK, Tiger Global, Pershing Square, Baupost and other widely-followed managers). “% of Fund” shows how much of that investor’s total 13F portfolio is invested in ACRS — a direct measure of their conviction.
Institutions that fully closed their ACRS position in Q2 2026
| 83.36% |
| +1.91 pp |
| $136M |
| 36% |
| Q4 2024 | 96 | +19% | 81.45% | 118.54 pp | $213M | +10% |
| Q3 2024 | 81 | — | 199.99% | — | $193M | — |
Source: SEC 13F institutional filings. Ownership % requires market cap data and will show once linked. Δ columns compare to the immediately prior filed quarter.
27 institutions opened new positions in ACRS during Q2 2026, while 15 fully exited. 104 added to existing positions and 16 trimmed.
ACRS institutional ownership rose by 6.92 percentage points quarter-over-quarter, with a net change of +12 holders.
The top 10 institutions account for 62.9% of all reported 13F value in ACRS, and the top 25 account for 86.5%.
All data is sourced from SEC Form 13F filings, which institutional investment managers with at least $100M in assets are required to file each quarter. We process every 13F filing from EDGAR and recompute the aggregates after each cycle. Insider transactions are sourced from Form 4 filings.
Aclaris Therapeutics, Inc. (ACRS) Institutional Ownership